Our research is aimed to develop low-cost and highly efficient asymmetric catalysts for practical uses in pharmaceutical syntheses, e.g. synthesis of intermediates that are of biological importance for natural products and/or ethical drug components. Chiral medicines have been recognized as the medicines of the future of high clinical relevancy, low toxicity and cost-effectiveness of low dosage as well as minimization of environment impact. This research is to address important issues towards the chemistry development in chiral medicines. Our approach includes rational design, synthesis and characterization of chiral ligands as well as the development of chiral complexes from the ligands by incorporation of metal ions with. The organ transformation of inexpensive pro-chiral substrates into requisite chiral compounds will be achieved using the developed chiral complexes as catalysts. The project is a logic extension of our development of chiral Schiff bases catalysts for reactions important to the construction of bioactive medicinal agents. Special motifs induced into chiral ligands are important for complexes to exhibit high enantioselectivity, high reactivity and stability. New chiral catalysts proposed in this project will take advantage of discovered disciplines to use the most effective steric effect groups and their positions capable of differentiating space for high enantioselectivity. The catalysts are designed to have Salen ligands that possess """"""""wall type"""""""" bulky groups to provide steric hindrance which is to be optimized with the position. Through this research, a clear correlation between microstructure and enantioselectivity will be established and efficient catalysts for practical application will be anticipated.

Project Start
2000-09-01
Project End
2001-08-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
13
Fiscal Year
2000
Total Cost
$69,492
Indirect Cost
Name
Clark Atlanta University
Department
Type
DUNS #
065325177
City
Atlanta
State
GA
Country
United States
Zip Code
30314
Ifere, Godwin O; Equan, Anita; Gordon, Kereen et al. (2010) Cholesterol and phytosterols differentially regulate the expression of caveolin 1 and a downstream prostate cell growth-suppressor gene. Cancer Epidemiol 34:461-71
Mariam, Yitbarek H; Musin, Ryza N (2008) Transition from moderate to strong hydrogen bonds: its identification and physical bases in the case of O-H...O intramolecular hydrogen bonds. J Phys Chem A 112:134-45
Kimbro, K Sean; Duschene, Kaitlin; Willard, Margeret et al. (2008) A novel gene STYK1/NOK is upregulated in estrogen receptor-alpha negative estrogen receptor-beta positive breast cancer cells following estrogen treatment. Mol Biol Rep 35:23-7
Chu, Qinghui; Pang, Yi (2004) Vibronic structures in the electronic spectra of oligo(phenylene ethynylene): effect of m-phenylene to the optical properties of poly(m-phenylene ethynylene). Spectrochim Acta A Mol Biomol Spectrosc 60:1459-67
Sannigrahi, Biswajit; McGeady, Paul; Khan, Ishrat M (2004) Helical poly(3-methyl-4-vinylpyridine)/amino acid complexes: preparation, characterization, and biocompatibility. Macromol Biosci 4:999-1007
Liang, Sidney; Bu, Xiu R (2002) Tertiary pentyl groups enhance salen titanium catalyst for highly enantioselective trimethylsilylcyanation of aldehydes. J Org Chem 67:2702-4
Vanderveer, Donald; Colon, Marisabel Lebron; Bu, Xiu R (2002) Crystal structure of a chiral Ni complex: (R,R)-N,N'-bis(3-t-butylsalicylidene)-1,2-cyclohexanediaminonickel(II). Anal Sci 18:1283-4
Musey, Paul I; Ibim, Sobrasua M; Talukder, Niranjan K (2002) Development of artificial blood vessels: seeding and proliferation characteristics of endothelial and smooth muscle cells on biodegradable membranes. Ann N Y Acad Sci 961:279-83
Chiang, C F; Okou, D T; Griffin, T B et al. (2001) Green fluorescent protein rendered susceptible to proteolysis: positions for protease-sensitive insertions. Arch Biochem Biophys 394:229-35
Johnson, K P; Rowe, G C; Jackson, B A et al. (2001) Novel antineoplastic isochalcones inhibit the expression of cyclooxygenase 1,2 and EGF in human prostate cancer cell line LNCaP. Cell Mol Biol (Noisy-le-grand) 47:1039-45

Showing the most recent 10 out of 17 publications